Exploring TNFi drug-levels and anti-drug antibodies during tapering among patients with inflammatory arthritis: secondary analyses from the randomised BIODOPT trial by Uhrenholt, L, Sørensen, MER, Lauridsen, KB, Duch, K, Dreyer, L, Christensen, R, Hauge, E-M, Loft, AG, Rasch, MNB, Horn, HC, Taylor, PC, Nielsen, KR, Kristensen, S

Disease activity-guided tapering of biologics in patients with inflammatory arthritis: a pragmatic, randomized, open-label, equivalence trial by Uhrenholt, L, Christensen, R, Dreyer, L, Hauge, E-M, Schlemmer, A, Loft, AG, Rasch, M, Horn, HC, Gade, KH, Østgård, RD, Taylor, PC, Duch, K, Kristensen, S